Melissa Russell tells PEOPLE that while daughter Leah's peers are going off to college and starting their own lives, she ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat neurological conditions like Huntington’s.

A 30-year-old man was treated for drug-resistant epilepsy through a procedure called temporal labectomy with amygdalo-hippocampectomy by doctors at Meenakshi Super Specialty Hospital.

NeuroPace provided initial financial guidance targets for 2025: Revenue of $92 million – $96 million, representing growth of 15.5% – 20.5% versus the midpoint of the expected 2024 revenue range of $79 ...

Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million Series B financing to ...

The change is expected to boost millions of people's credit scores and helping them qualify for home mortgages. It's unclear ...

Mystery surrounds the death of a “loveable” and “cheeky” man who struggled with alcohol misuse, an inquest has heard. Paul ...

Atalanta Therapeutics is pioneering RNA interference (RNAi) for the treatment of neurological diseases, having developed a proprietary platform that, for the first time enables RNAi to be deployed ...

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into Phase I trials, with additional preclinical assets targeting Parkinson’s and ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

Seven different doctors dismissed her theory, she says, before one finally agreed to test Walilko’s boyfriend—who was ...

Stifel analysts maintained a Buy rating and a $72.00 price target for LivaNova (NASDAQ:LIVN), following news from Swedish ...